Patent ID: 8377978

Claim:
A method of treating a disorder or a disease associated with neutral endopeptidase EC. 3.4. 24.11. activity in a subject in need thereof, comprising: administering to the subject a therapeutically effective amount of a compound formula (I′): wherein: X 1 is OH, —O—C 1-7 alkyl, —NR a R b , —NHS(O) 2 —C 1-7 alkyl or —NHS(O) 2 -benzyl, wherein R a and R b for each occurrence are independently H or C 1-7 alkyl; R 1 is H, C 1-6 alkyl or C 6-10 -aryl-C 1-6 alkyl, wherein alkyl is optionally substituted with benzyloxy, hydroxy or C 1-6 alkoxy; for each occurence, R 2 is independently C 1-6 -alkoxy, hydroxy, halo, C 1-6 -alkyl, cyano or trifluoromethyl; A 2 is 0 or NR 5 ; R 4 and R 5 are independently H or C 1-6 alkyl; A 1 is a bond or C 1-3 alkylene chain; R 3 is a 5-or 6-membered heteroaryl, C 6-10 -aryl or C 3-7 -cycloalkyl, wherein each heteroaryl, aryl or cycloalkyl are optionally substituted with one or more groups independently selected from the group consisting of C 1-6 alkyl, halo, haloC 1-6 alkyl, C 1-6 alkoxy, hydroxy, CO 2 H and CO 2 C 1-6 alkyl; R 6 for each occurrence is independently halo, hydroxy, C 1-7 alkoxy, halo, C 1-7 alkyl or halo-C 1-7 akyl; or R 4 , A 1 -R 3 , together with the nitrogen to which R 4 and A 1 -R 3 are attached, form a 4- to 7-membered heterocyclyl or a 5- to 6-membered heteroaryl , each of which is optionally substituted with one or more groups independently selected from the group consisting of C 1-6 alkyl, halo, haloC 1-6 alkyl, C 1-6 alkoxy, hydroxy, CO 2 H and CO 2 C 1-6 alkyl; and m is 0 or an integer from 1 to 5; s is 0 or an integer from 1 to 4; or a pharmaceutically acceptable salt thereof; and wherein the disorder is selected from hypertension, pulmonary hypertension, isolated systolic hypertension, resistant hypertension, peripheral vascular disease, congestive heart failure or pulmonary arterial hypertension.